London
Roots Analysis has announced theaddition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings.
Overtime, extensive R&D on the potential health benefits of cannabis, haveenabled medical researchers to identify a number of pharmacologically activeingredients that offer clinical benefit, minus the addictive properties of thecrude substance. Currently, several stakeholders in the pharmaceutical industryare actively engaged in the efforts to develop leads based on natural andsynthetic derivatives of cannabinoids.
To order this 250+ page report, whichfeatures 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html
Key MarketInsights
Over 175 drugstargeting the endocannabinoid system are currently under development
Most cannabinoid-baseddrug candidates are being developed to target the CB1 and CB2 receptors. Nearly45% of such drugs are presently being investigated in clinical trials, while 50%are in the preclinical / discovery phase. Majorityof these therapies (60%) are designed for oral administration.
More than60 companies claim to develop endocannabinoid system targeted therapeutics
Post2010, there has been a significant rise in the number of companies working inthis domain; such companies represent 63% of the total number of players. Majorityof the firms engaged in this domain (74%) are based in North America, followedby those headquartered in Asia-Pacific (16%), Europe (8%) and Latin America(2%).
Partnershipactivity has grown at an annualized rate of 35%, between 2017 and 2019
The maximumnumber of partnerships were observed in 2019 within this segment of thepharmaceutical industry. Majority of these agreements were reported to have beeninked for research purposes (20%). In addition, more than 35 merger /acquisition deal were signed between 2016 and 2020; service / facilityexpansion emerged as the most prominent key value drivers for such agreements.
Close to 600grants were awarded for supporting research on endocannabinoid system targetedtherapeutics, since 2016
Almost 45%of the total amount awarded in the form of grants, was under the R01 (insupport of health-related research and development based on the mission ofthe NIH) mechanism. Further, grants (394) worth USD 147 million wereawarded to research projects related to endocannabinoid system.
For additional details, pleasevisit
https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.htmlor email sales@rootsanalysis.com
You may also be interested in thefollowing titles:
1. Neoantigen Targeted Therapies Market, 2019-2030
2. Blood-Brain Barrier (BBB) Market (2ndEdition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platformsand Therapeutics
3. Bispecific Antibody Therapeutics Market(4th Edition), 2019-2030
4. Continuous Manufacturing Market (Small Molecules and Biologics),2020 – 2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
